Skip to main
ALLR

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics Inc is positioned favorably due to its attractive current valuation, supported by net present value (NPV) analysis that indicates significant upside potential. The company’s lead therapeutic candidate, stenoparib, has demonstrated promising and durable clinical benefits, particularly in patients with advanced recurrent ovarian cancer, with recent data showing a median overall survival exceeding 25 months in its Phase 2 trial. This combination of robust clinical results and a favorable valuation strategy suggests a compelling growth opportunity for investors, balancing inherent risks with the promise of substantial returns.

Bears say

Allarity Therapeutics Inc reported a net loss of $2.8 million, translating to an EPS of $(0.19), which fell short of expectations, indicating potential financial instability. The company continues to face significant risks associated with its product development, including potential failures in demonstrating safety and efficacy, regulatory approvals, and commercialization efforts, which could adversely affect its financial outlook. Additionally, ongoing balance sheet and liquidity concerns, coupled with broader market factors, further contribute to a negative perspective on the company's stock performance.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.